Leaflet: information for the user
Dexdor 100micrograms/mL concentrated solution for infusion
dexmedetomidine
Read this leaflet carefully before you start using this medicine, because it contains important information for you.
1. What is Dexdor and what it is used for
2. What you need to know before you are given Dexdor
3. How to use Dexdor
4. Possible side effects
5. Storage of Dexdor
6. Contents of the pack and additional information
Dexdor contains an active substance called dexmedetomidine, which belongs to a group of medicines called sedatives. It is used to provide sedation (a state of calmness, drowsiness, or sleep) in adult patients in intensive care units of hospitals or conscious sedation during various diagnostic or surgical procedures.
Do not administer Dexdor
Warnings and precautions
Before using this medication, inform your doctor or nurse if you are in any of the following situations, as Dexdor should be used with caution:
Use of Dexdor with other medications
Inform your doctor or nurse if you are using, have used recentlyor may need to use any other medication.
The following medications may increase the effect of Dexdor:
If you are using medications that lower your blood pressure and heart rate, the concurrent administration with Dexdor may increase this effect.Dexdor should not be used with medications that can cause temporary paralysis.
Pregnancy and breastfeeding
Dexdor should not be used during pregnancy or breastfeeding, unless clearly necessary.
Consult your doctor beforeusing thismedication.
Driving and operating machines
Dexdor has a significant impact on your ability to drive and operate machines. Once Dexdor has been administered, do not drive, operate machines, or work in hazardous situations until the effects have completely passed. Consult your doctor when you can resume these activities and this type of work.
Excipients
Dexdor contains less than 1 mmol of sodium (23 mg) per ml; this is essentially “sodium-free”.
Intensive Care Hospital Care
Dexdor is administered by a doctor or nurse in the intensive care unit of a hospital.
Procedure Sedation / Conscious Sedation
A doctor or nurse will administer Dexdor before and/or during diagnostic or surgical procedures that require sedation, e.g. procedure sedation / conscious sedation.
Your doctor will decide on the appropriate dose for you. The amount of Dexdor depends on your age, body weight, overall health, the level of sedation required, and how you respond to the medication. Your doctor may adjust your dose as needed and will monitor your heart and blood pressure during treatment.
Dexdor is diluted and administered as an infusion (drip) into your veins.
After Sedation/Waking Up
If You Have Been Given MoreDexdorThan You Should
If you have been given too much Dexdor, your blood pressure may rise or fall, your heart rate may be slower, you may breathe more slowly, and you may feel more drowsy. Your doctor will know how to treat you based on your condition.
If you have any other questions about the use of this medication, ask your doctor.
Like all medications, this medication may produce adverse effects, although not all people will experience them.
Very frequent (affects more than 1 in 10 users)
Frequent (affects between 1 and 10 in 100 users)
Rare (affects between 1 and 10 in 1,000 users)
Unknown frequency ( cannot be estimated from available data )
Reporting Adverse Effects
If you experience adverse effects, consult your doctor or nurse, even if they are possible adverse effects that do not appear in this prospectus. You can also report them directly through the national notification system included in the Appendix V . By reporting adverse effects, you can contribute to providing more information about the safety of this medication.
Keep this medication out of the sight and reach of children.
Do not use this medication after the expiration date that appears on the label and packaging after CAD.
This medication does not require any special storage temperature. Storeampoules or vials in the outer packaging to protect it from light.
Composition of Dexdor
Each ampoule of 2 ml contains 200 micrograms of dexmedetomidine (as hydrochloride).
Each vial of 2 ml contains 200 micrograms of dexmedetomidine (as hydrochloride).
Each vial of 4 ml contains 400 micrograms of dexmedetomidine (as hydrochloride).
Each vial of 10 ml contains 1000 micrograms of dexmedetomidine (as hydrochloride).
The concentration of the final solution after dilution should be 4 micrograms/ml or 8 micrograms/ml.
Aspect of the product and content of the packaging
Concentrate for solution for infusion (sterile concentrate).
The concentrate is a transparent and colorless solution.
Containers
2 ml glass ampoules
2, 5 or 10 ml glass vials
Container sizes
5 ampoules with 2 ml
25 ampoules with 2 ml
5 vials with 2 ml
4 vials with 4 ml
4 vials with 10 ml
Only some container sizes may be commercially available.
Marketing Authorization Holder
Orion Corporation
Orionintie 1
FI-02200 Espoo
Finland
Responsible for manufacturing
Orion Corporation Orion Pharma
Orionintie 1
FI-02200 Espoo
Finland
For more information about this medicinal product, please contact the local representative of the marketing authorization holder:
België/Belgique/Belgien Luxembourg/Luxemburg Orion Pharma BVBA/SPRL Tél/Tel: +32 (0)15 64 10 20 | |
Nederland Orion Pharma BVBA/SPRL Tel: +32 (0)15 64 10 20 | Danmark Orion Pharma A/S Tlf: + 45 8614 00 00 |
Ceská republika Orion Pharma s.r.o. Tel: +420 234 703 305 | Eesti Orion Pharma Eesti Oü Tel: +372 6 644 550 |
Deutschland Österreich Orion Pharma GmbH Tel: + 49 40 899 6890 | España Orion Pharma S.L. Tel: + 34 91 599 86 01 |
Ελλ?δα Orion Pharma Hellas M.E.Π.E Τηλ: + 30 210 980 3355 | Ireland Orion Pharma (Ireland) Ltd. Tel: + 353 1 428 7777 |
France Centre Spécialités Pharmaceutiques Tel: + 33 (0) 1 47 04 80 46 | Italia Orion Pharma S.r.l. Tel: + 39 02 67876111 |
Ísland Vistor hf. Simi: +354 535 7000 | Latvija Orion Corporation in Latvia Tel: + 371 6745 5569 |
Κ?προς Lifepharma (ZAM) Ltd Τηλ.: +357 22347440 | Magyarország Orion Pharma Kft. Tel.: +36 1 239 9095 |
Lietuva UAB Orion Pharma Tel: +370 5 276 9499 | Polska Orion Pharma Poland Sp. z.o.o. Tel.: + 48 22 8 333 177 |
Norge Orion Pharma AS Tlf: + 47 4000 4210 | Slovenija Orion Pharma d.o.o. Tel: +386 (0) 1600 8015 |
Portugal Orionfin Unipessoal Lda Tel: + 351 21 154 68 20 | Suomi/Finland Orion Corporation Puh/Tel: + 358 10 4261 |
???????? Orion Pharma Poland Sp. z.o.o. ???.: + 48 22 8 333 177 | Hrvatska PHOENIX Farmacija d.o.o. Tel: +385 1 6370450 |
Malta Orion Corporation Tel: + 358 10 4261 | România Orion Corporation Tel: + 358 10 4261 |
Slovenská republika Orion Pharma s.r.o. Tel: +420 234 703 305 | United Kingdom Orion Pharma (UK) Ltd. Tel: + 44 1635 520 300 |
Sverige Orion Pharma AB Tel: + 46 8 623 6440 |
Last review date of this leaflet:
For detailed information about this medicinal product, please visit the website of the European Medicines Agency:http://www.ema.europa.eu.
-----------------------------------------------------------------------------------------------------------------------
This information is intended for healthcare professionals only:
Dexdor 100 micrograms/ml concentrate for solution for infusion
Administration
Dexdor should be administered by healthcare professionals experienced in the care of patients requiring intensive care or in the management of anesthesia in patients undergoing surgery.It should be administered only as a diluted intravenous infusion using a controlled infusion device.
Preparation of the solution
Dexdor can be diluted in glucose 50 mg/ml (5%), Ringer's solution, mannitol or sodium chloride 9 mg/ml (0.9%) solution for injection to achieve the required concentration of 4 micrograms/ml or 8 micrograms/ml before administration. See below for the volumes required to prepare the infusion.
When a concentration of 4 micrograms/ml is required:
Volume of Dexdor 100 micrograms/ml concentrate for solution for infusion | Volume of diluent | Total infusion volume |
2 ml | 48 ml | 50 ml |
4 ml | 96 ml | 100 ml |
10 ml | 240 ml | 250 ml |
20 ml | 480 ml | 500 ml |
When a concentration of 8 micrograms/ml is required:
Volume of Dexdor 100 micrograms/ml concentrate for solution for infusion | Volume of diluent | Total infusion volume |
4 ml | 46 ml | 50 ml |
8 ml | 92 ml | 100 ml |
20 ml | 230 ml | 250 ml |
40 ml | 460 ml | 500 ml |
The solution should be gently agitated to mix well.
Dexdor should be visually inspected for particles and color before administration.
Dexdor has been shown to be compatible when administered with the following intravenous fluids and medications:
Ringer's lactate solution, glucose 5% solution, sodium chloride 0.9% solution, mannitol 20%, thiopental sodium, etomidate, vecuronium bromide, pancuronium bromide, succinylcholine, atracurium besilate, mivacurium chloride, rocuronium bromide, glycopyrrolate bromide, phenylephrine HCl, atropine sulfate, dopamine, noradrenaline, dobutamine, midazolam, morphine sulfate, fentanyl citrate, and a plasma substitute.
Compatibility studies have shown potential for dexmedetomidine to adsorb to some types of natural rubber. Although dexmedetomidine is dosed based on effect, it is recommended to use components with synthetic or natural rubber-coated joints.
Expiry date
Chemical and physical stability has been demonstrated in use for 24 hours at 25°C.
From a microbiological point of view, the product should be used immediately. If not used immediately, the storage times and conditions prior to use are the responsibility of the user and should not normally be longer than 24 hours between 2°C and 8°C, unless the dilution has been prepared in controlled and validated aseptic conditions.
Есть вопросы по этому лекарству или вашим симптомам? Свяжитесь с лицензированным врачом для получения помощи и персонализированного ухода.